Plain-English translation of NCT07016230 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new drug called to treat advanced small-cell lung cancer and other rare neuroendocrine cancers that have spread or cannot be surgically removed. works by targeting a specific protein on cancer cells. Researchers want to understand how well this medication works and why some patients respond better than others by collecting blood and tumor samples throughout the trial.
Small-cell lung cancer and neuroendocrine cancers are aggressive tumors with limited treatment options, especially after standard chemotherapy. This trial aims to find a new treatment option and understand which patients are most likely to benefit from this medication.
You will receive intravenous infusions of the medication on a set schedule: a smaller dose on day 1, then larger doses on days 8 and 15, followed by doses every two weeks in 28-day cycles. You will continue treatment until your cancer progresses, you experience unacceptable side effects, or you choose to withdraw. Throughout the trial, you will have regular blood tests and undergo biopsies of your tumor before starting treatment, while receiving treatment, and when your cancer stops responding to measure how the medication is working and to help researchers understand why some patients benefit more than others.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
France